Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03563677
Other study ID # ZSE-DUO_V1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 15, 2018
Est. completion date September 30, 2022

Study information

Verified date December 2023
Source Wuerzburg University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In people suffering from a rare disease the diagnostic process and the confirmation of a final diagnosis is often ongoing for many years. Factors contributing to delayed diagnosis include the limited knowledge of health care professionals about rare diseases and their symptoms but also a psychiatric or psychosomatic (co-)morbidity obscuring the symptoms of the rare disease. The project ZSE-DUO will evaluate whether a combination of an expert in somatic medicine and a psychiatric/psychosomatic specialist will increase the rate of assured diagnoses in patients approaching a center of rare diseases (primary outcome), accelerate the process until a diagnosis is made, reduce the costs of diagnosing a patient, and lead to a higher satisfaction of patients and health care professionals. Furthermore, the project will evaluate whether the use of psychosomatic screening tools at registration of a patient in a center for rare diseases will help to guide the diagnostic process. Two cohorts of 682 patients each will be sequentially recruited over 9 plus 9 months: the Control group cohort (CG based on somatic expertise) and the Experimental group cohort (EG combined psychosomatic/somatic expertise Included will be persons from the age of at least 12 years presenting with symptoms and signs which are not explained by current diagnoses (as judged by the patient's primary care physician and a specialized physician at the center for rare diseases ZSE evaluating the medical records). Patients will be recruited from 11 German Centers for Rare Diseases associated with University hospitals in the cities of Aachen, Bochum, Frankfurt, Hannover, Magdeburg, Mainz, Münster, Regensburg, Tübingen, Ulm and Würzburg. Recruitment will be supported by a collaboration with the German patient organization representing many rare disease organizations ACHSE e.V. and a collaboration with the insurance companies Techniker Krankenkasse, IKK gesund plus and AOK Hessen who also provide data on costs of care. Data collection and analysis will be coordinated and performed by the Institute for Clinical Epidemiology and Biometry at the University of Würzburg, the Institute for Epidemiology, Social Medicine and Science of Health Care Systems in Hannover, and the Department of Medical Psychology in Hamburg. The project is funded by the Innovationsfond of the Federal Joint Committee in Germany.


Recruitment information / eligibility

Status Completed
Enrollment 1379
Est. completion date September 30, 2022
Est. primary completion date January 31, 2022
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: - first contact with the Center for Rare Diseases for unclear diagnosis - suspicion of a rare disease but no established diagnosis - attending the Center for Rare Diseases as an outpatient - written informed consent Exclusion Criteria: - age <12 years - incomplete medical records including summary letters, imaging studies, blood tests etc. - pre-diagnosed disease(s) explaining all symptoms

Study Design


Related Conditions & MeSH terms


Intervention

Other:
dual expert guidance structure
Two medical experts, one somatic specialist and one psychiatrist/psychosomatic specialist see all medical records and the patients together

Locations

Country Name City State
Germany Center for Rare Diseases ZSEA, University Hospital Aachen
Germany Center for Rare Diseases CeSER, St. Josef Hospital Bochum
Germany LWL-Universitätsklinikum der Ruhr-Universität Bochum
Germany Center for Rare Diseases FRZSE, UNiversity Hospital Frankfurt
Germany Center for Rare Diseases, Hannover Medical School Hannover
Germany Center for Rare Diseases MKSE, Otto von Guericke University Magdeburg
Germany Center for Rare Diseases, Medical Center Mainz
Germany Center for Rare Diseases, University Hospital Muenster
Germany Center for Rare Diseases ZSER, University Hospital Regensburg
Germany Center for Rare Diseases, University Hospital Tuebingen
Germany Center for Rare Diseases, University Hospital Ulm
Germany Center for Rare Diseases ZESE, University Hospital Würzburg Bavaria

Sponsors (18)

Lead Sponsor Collaborator
Wuerzburg University Hospital Allianz Chronischer Seltener Erkrankungen ACHSE e.V., AOK Hessen, Goethe University, Hannover Medical School, IKK gesund plus, LWL-Universitätsklinikum der Ruhr-Universität Bochum, Otto-von-Guericke University Magdeburg, St. Josef Hospital Bochum, Techniker Krankenkasse, Universität Münster, Universitätsklinikum Hamburg-Eppendorf, University Hospital Regensburg, University Hospital Tuebingen, University Hospital Ulm, University Hospital, Aachen, University Medical Center Mainz, University of Wuerzburg

Country where clinical trial is conducted

Germany, 

References & Publications (4)

Hebestreit H, Lapstich AM, Brandstetter L, Krauth C, Deckert J, Haas K, Pfister L, Witt S, Schippers C, Dieris-Hirche J, Maisch T, Tuscher O, Barlescu L, Berger A, Berneburg M, Britz V, Deibele A, Graessner H, Gundel H, Heuft G, Lucke T, Mundlos C, Quitma — View Citation

Hebestreit H, Zeidler C, Schippers C, de Zwaan M, Deckert J, Heuschmann P, Krauth C, Bullinger M, Berger A, Berneburg M, Brandstetter L, Deibele A, Dieris-Hirche J, Graessner H, Gundel H, Herpertz S, Heuft G, Lapstich AM, Lucke T, Maisch T, Mundlos C, Petermann-Meyer A, Muller S, Ott S, Pfister L, Quitmann J, Romanos M, Rutsch F, Schaubert K, Schubert K, Schulz JB, Schweiger S, Tuscher O, Ungethum K, Wagner TOF, Haas K; ZSE-DUO working group. Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study. Orphanet J Rare Dis. 2022 Feb 14;17(1):47. doi: 10.1186/s13023-022-02176-1. — View Citation

Schippers C, Volk D, de Zwaan M, Deckert J, Dieris-Hirche J, Herpertz S, Schulz JB, Hebestreit H; ZSE-DUO Arbeitsgruppe. [ZSE-DUO - dual guidance structure at the centre for rare diseases]. Inn Med (Heidelb). 2022 Jul;63(7):791-797. doi: 10.1007/s00108-022-01350-8. Epub 2022 Jun 2. German. — View Citation

Witt S, Kristensen K, Blomeke J, Hebestreit H, Wocker M, Pfister L, Bullinger M, Tuscher O, Deckert J, Graessner H, Lapstich AM, Zwaan M, Mundlos C, Quitmann JH. [Quality of Life and Experienced Distress of Patients Suspected of having a Rare (Chronic) He — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnoses made The number of diagnoses explaining the symptomatology of the patient made during the evaluation process 12 months after signing the consent form
Secondary Time to diagnosis The time it takes to make a diagnosis 12 months after signing the consent form
Secondary Patient satisfaction with diagnostic process using ZUF-8 The patients' satisfaction with the diagnostic process is assessed in the total sample with the questionnaire ZUF-8 (Fragebogen zur Patientenzufriedenheit - patient satisfaction questionnaire) and in a randomly selected subsample of about 40 patients by structured telephone interviews. 12 months after signing the consent form
Secondary Costs of the diagnostic process estimated costs from first contact with the center for rare diseases until a diagnosis explaining the symptoms has been established up to 12 months after signing the consent from
Secondary Patients' quality of life using EQ-5D and SF12 (or KIDSCREEN-10 for children) Change in the patients' quality of life as assessed with the Quality of life questionnaires EQ-5D from the EuroQoL Group in all patients and Short Form 12 (SF-12) in patients 16 years and older. In patients younger than 16 years, the health-related quality of life questionnaire for children and adolescents KIDSCREEN-10 is used. 12 months after signing the consent from
Secondary Physician satisfaction with new form of care using new questionnaire The satisfaction of physicians working in the Centers fro Rare Diseases with the new form of care compared to standard care will be assessed by a newly developed questionnaire administered to all physicians involved in patient care in the 11 centers. For the development of the questionnaire, 3 focus groups of 10 physicians each will be questioned. 30 months after the project start (end of the intervention period)
Secondary Value of screening instruments for psychiatric-psychosomatic (co-)morbidities Performance of screening tools to identify patients with psychiatric-psychosomatic comorbidities against the judgement of a psychiatrist/psychosomatic expert seeing the patient (intervention group only) 30 months after the project start (end of intervention period)
See also
  Status Clinical Trial Phase
Recruiting NCT05794217 - A Multi-Site Leukopak Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives
Completed NCT03680365 - Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
Completed NCT03290469 - NICUSeq: A Trial to Evaluate the Clinical Utility of Human Whole Genome Sequencing (WGS) Compared to Standard of Care in Acute Care Neonates and Infants N/A
Not yet recruiting NCT05955794 - Vocal Pattern Assessment as a New Key to Identifying Rare Syndromes N/A
Recruiting NCT04429750 - Intact Cord Resuscitation in CDH N/A
Not yet recruiting NCT04152876 - Functional Genomics of Rare Genetic Diseases: Realization of Innovative Tools With High Diagnostic Power
Recruiting NCT03683966 - MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study
Not yet recruiting NCT04319796 - European Registry on Rare Neurological Diseases
Completed NCT02736565 - Pbi-shRNAâ„¢ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma Phase 1
Completed NCT05070988 - Oral Health Related Quality of Life of Patients With Rare Diseases: a Qualitative Approach
Recruiting NCT05499091 - Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN N/A
Completed NCT03954652 - Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - "GENOME FIRST APPROACH" N/A
Recruiting NCT05703893 - Investigation of the Neurovegetative Pattern in Patients With Thoracic Aortic Aneurysms (TAA)
Enrolling by invitation NCT04703179 - Rare and Undiagnosed Disease Research Biorepository
Recruiting NCT04024774 - Diagnostic Research in Patients With Rare Diseases -Solving the Unsolved Rare Diseases
Recruiting NCT06343558 - Gait and Balance Impairment in Rare and Very Rare Neurological Diseases
Not yet recruiting NCT06412718 - Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Enrolling by invitation NCT04654000 - Rheopheresis as Adjuvant Treatment of Calciphylaxis N/A
Recruiting NCT04651439 - Severe Bullous Drug Eruption and Filgrastim Phase 2/Phase 3
Recruiting NCT03491280 - Diagnostic Research in Patients With Rare Diseases - Solving the Unsolved Rare Diseases